Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Lisa Derosa, Laurence Albiges, Christophe Massard, Yohann Loriot, Karim Fizazi & Bernard Escudier. (2016) Safety of available treatment options for renal cell carcinoma. Expert Opinion on Drug Safety 15:8, pages 1097-1106.
Read now
Read now
Andrea Zivi, Linda Cerbone, Federica Recine & Cora N Sternberg. (2012) Safety and tolerability of pazopanib in the treatment of renal cell carcinoma. Expert Opinion on Drug Safety 11:5, pages 851-859.
Read now
Read now
Articles from other publishers (12)
Cecilie Budolfsen, Julie Faber, Daniela Grimm, Marcus Krüger, Johann Bauer, Markus Wehland, Manfred Infanger & Nils Erik Magnusson. (2019) Tyrosine Kinase Inhibitor-Induced Hypertension: Role of Hypertension as a Biomarker in Cancer Treatment. Current Vascular Pharmacology 17:6, pages 618-634.
Crossref
Crossref
Chris Plummer, Agnieszka Michael, Ghazia Shaikh, Michael Stewart, Lynn Buckley, Tracie Miles, Agnes Ograbek & Terry McCormack. (2019) Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK. British Journal of Cancer 121:2, pages 109-116.
Crossref
Crossref
Bertrand F. Tombal, Christine Remacle & Monique Kasa Vubu. 2018. Side Effects of Medical Cancer Therapy. Side Effects of Medical Cancer Therapy
179
212
.
Francesco Massari, Chiara Ciccarese, Davide Bimbatti, Emanuela Fantinel, Alessandra Modena, Michele Simbolo, Matteo Brunelli, Walter Artibani, Guido Martignoni, Aldo Scarpa & Giampaolo Tortora. (2015) Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma. Anti-Cancer Drugs 26:4, pages 469-473.
Crossref
Crossref
M. Dror Michaelson & Walter M. Stadler. (2013) Predictive Markers in Advanced Renal Cell Carcinoma. Seminars in Oncology 40:4, pages 459-464.
Crossref
Crossref
Bertrand F. Tombal. 2013. Side Effects of Medical Cancer Therapy. Side Effects of Medical Cancer Therapy
247
292
.
S. George, P. Reichardt, T. Lechner, S. Li, D.P. Cohen & G.D. Demetri. (2012) Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib. Annals of Oncology 23:12, pages 3180-3187.
Crossref
Crossref
T. Eisen, C. N. Sternberg, C. Robert, P. Mulders, L. Pyle, S. Zbinden, H. Izzedine & B. Escudier. (2012) Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies. JNCI Journal of the National Cancer Institute 104:2, pages 93-113.
Crossref
Crossref
Hassan Izzedine, Sylvie Négrier, Yann Neuzillet & Laurent Zini. (2011) Gestion des effets secondaires des thérapies ciblées dans le cancer du rein : effets secondaires néphrologiques. Bulletin du Cancer 98:3, pages S7-S18.
Crossref
Crossref
A. Bamias, E. Manios, A. Karadimou, F. Michas, G. Lainakis, C. Constantinidis, C. Deliveliotis, N. Zakopoulos & M.A. Dimopoulos. (2011) The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer. European Journal of Cancer 47:11, pages 1660-1668.
Crossref
Crossref
Ziya Kirkali. (2011) Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use. BJU International 107:11, pages 1722-1732.
Crossref
Crossref
B. I. Rini, D. P. Cohen, D. R. Lu, I. Chen, S. Hariharan, M. E. Gore, R. A. Figlin, M. S. Baum & R. J. Motzer. (2011) Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. JNCI Journal of the National Cancer Institute 103:9, pages 763-773.
Crossref
Crossref